The authors make no claims of the accuracy of the information contained
herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this document shall be liable for any special,
consequential, or exemplary damages resulting in whole or part from any
user's use of or reliance upon this material. PLEASE
READ THE DISCLAIMER CAREFULLY BEFORE
ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE
TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.
Usual Diluents
Not applicable - Premix Bags - 0.8% saline
Standard Dilutions [Amount of drug]
[Infusion volume] [Infusion rate]
[ 400 mg ] [ 250 ml ] [ 1 hour ]
Premix Bags: AVELOX I.V. (moxifloxacin hydrochloride in sodium chloride
injection) is available in ready-to-use 250 mL latex-free flexible bags
containing 400 mg of moxifloxacin in 0.8% saline. NO FURTHER DILUTION OF
THIS PREPARATION IS NECESSARY.
Stability / Miscellaneous
Label: DO NOT REFRIGERATE – PRODUCT PRECIPITATES UPON
REFRIGERATION
AVELOX I.V. should be administered by INTRAVENOUS infusion only.
DOSAGE AND ADMINISTRATION: The dose of AVELOX is 400
mg (orally or as an intravenous infusion) once every 24 hours.
For Complicated Intra-Abdominal Infections, therapy should be initiated
with the intravenous formulation. When switching from intravenous to
oral dosage administration, no dosage adjustment is necessary. Patients
whose therapy is started with AVELOX I.V. may be switched to AVELOX
Tablets when clinically indicated at the discretion of the physician.
Infection
Daily
Dose
Duration
Acute Bacterial
Sinusitis
400 mg
10 days
Acute Bacterial
Exacerbation of Chronic Bronchitis
400 mg
5 days
Community Acquired
Pneumonia
400 mg
7-14 days
Uncomplicated Skin
and Skin Structure Infections
400 mg
7 days
Complicated Skin
and Skin Structure Infections
400 mg
7-21 days
Complicated
Intra-Abdominal Infections
400 mg
5-14 days
Impaired Renal Function:
No dosage adjustment is required in renally impaired patients,
including those on either hemodialysis or continuous ambulatory
peritoneal dialysis.
Parenteral drug products should be inspected visually for particulate
matter prior to administration. Samples containing visible particulates
should not be used.
Since the premix flexible containers are for single-use only, any
unused portion should be discarded. Store at 25°C (77°F); excursions
permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature].
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER
CAREFULLY
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.